

Medical Drug Clinical Criteria

Subject: Blenrep (belantamab mafodotin-blmf)

Document #: CC-0295

Publish Date: 01/30/2026

Status: New

Last Review Date: 12/08/2025

Table of Contents

[Overview](#)

[Coding](#)

[References](#)

[Clinical Criteria](#)

[Document History](#)

Overview

Blenrep (belantamab mafodotin-blmf), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, is FDA indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

The National Comprehensive Cancer Network® (NCCN) provides additional recommendations with a category 2A level of evidence for the use of Blenrep as therapy for previously treated multiple myeloma for relapsed/refractory disease in patients who have received at least three prior lines of therapy (useful in certain circumstances). NCCN also provides a category 1 level of evidence for the use of Blenrep as therapy for previously treated multiple myeloma for relapsed/refractory disease in combination with dexamethasone and bortezomib in patients who have received at least two prior therapies including a proteasome inhibitor and an immunomodulatory agent.

Other Uses

NCCN also provides guidance for use of Blenrep in the treatment of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) (useful in certain circumstances), Monoclonal Immunoglobulin Deposition Disease (MIDD), and plasma cell-related Monoclonal Gammopathy of Renal Significance (MGRS).

Definitions and Measures

Line of Therapy:

- First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
- Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
- Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.

Multiple myeloma: A type of cancer that begins in plasma cells (white blood cells that produce antibodies).

Proteasome inhibitors: A class of drugs used to treat multiple myeloma that work by blocking the action of proteasomes which are cellular complexes that break down proteins. Examples include bortezomib, carfilzomib and ixazomib.

Refractory Disease: Illness or disease that does not respond to treatment.

Relapse or recurrence: After a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Blenrep (belantamab mafodotin-blmf)

Requests for Blenrep (belantamab mafodotin-blmf) may be approved if the following criteria are met:

- I. Individual is under 19 years of age;
OR
- II. Individual has a diagnosis of relapsed or refractory multiple myeloma (Label, NCCN 1); **AND**
- III. Individual is using in one of the following ways:
 - A. Individual is using in combination with bortezomib and dexamethasone; **AND**
 - B. Individual has had at least two prior therapies, including a proteasome inhibitor (e.g. bortezomib, ixazomib, or carfilzomib) and an immunomodulatory agent (e.g. lenalidomide or pomalidomide);
OR
 - C. Individual is using as a single agent (NCCN 2A); **AND**
 - D. Individual has received at least three prior lines of therapy.

Blenrep (belantamab mafodotin-blmf) may not be approved when the above criteria are not met and for all other indications.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

C9399	Unclassified drugs or biologicals [when specified as Blenrep (belantamab mafodotin-blmf)]
J9999	Not otherwise classified, antineoplastic drugs [when specified as Blenrep (belantamab mafodotin-blmf)]

ICD-10 Diagnosis

C90.00-C90.32	Multiple myeloma and malignant plasma cell neoplasms
---------------	--

Document History

New: 12/08/2025

Document History:

- 12/08/2025 – Select Review: New PA criteria for Blenrep. Added HCPCS NOC C9399, J9999 for Blenrep and ICD-10-CM C90.00-C90.32.

References

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: November 3, 2025
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
4. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on December 1, 2025.
 - a. Multiple Myeloma. V4.2026. Revised November 26, 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association